Core Viewpoint - A class action lawsuit has been filed against C3.ai, alleging that the company and its executives misled investors regarding its financial health and growth prospects, violating the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., claims that C3.ai provided overly optimistic revenue projections while downplaying risks associated with CEO Thomas M. Siebel's health issues [2][3]. - The class period for the lawsuit is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline set for October 21, 2025 [2][4]. - Following a disappointing financial announcement on August 8, 2025, C3.ai's stock price dropped by more than 25% after the company lowered its revenue guidance for the fiscal year [3]. Group 2: Company Performance and Leadership Impact - C3.ai attributed its poor financial results to "reorganization with new leadership" and the health problems of CEO Thomas M. Siebel [3]. - The lawsuit emphasizes that C3.ai's public statements regarding growth and profitability were deemed "unrealistic" and overly reliant on Siebel's health and performance [2][5]. Group 3: Investor Actions - Investors who suffered significant losses during the class period are encouraged to submit their claims and may seek to serve as lead plaintiffs [2][4]. - The firm leading the investigation is focused on whether C3.ai's public statements adequately disclosed the impact of Siebel's health on the company's financial targets [5].

Core Insights - C3.ai, Inc. (AI) started fiscal 2026 with profitability concerns as non-GAAP gross margin decreased to 52%, down 1,800 basis points from 70% in the previous year, primarily due to higher initial production deployment costs and reduced revenues from demonstration licenses [1][9] - The shift towards initial production deployments (IPDs) indicates both growth potential and margin risks, with management expecting moderate gross margins in the near term as support capacity is built [2] - Subscription revenues remained strong, contributing $60.3 million, or 86% of total revenues, while liquidity is robust with $711.9 million in cash, although negative free cash flow of $34.3 million highlights ongoing investment intensity [3] Financial Performance - C3.ai's gross margin contraction reflects the challenges of scaling new deployments, impacting the path to achieving non-GAAP profitability and free cash flow [1][3] - The company’s reliance on upfront-cost-heavy IPDs contrasts with peers like Palantir and Snowflake, which are demonstrating profitable scaling with strong margins [7] - C3.ai's stock has declined 23.6% over the past three months, compared to a 6.1% decline in the industry [8] Peer Comparison - Palantir Technologies Inc. reported an adjusted gross margin of 82% in Q2 2025, enabling a 46% adjusted operating margin and robust free cash flow of $569 million [5] - Snowflake Inc. achieved a non-GAAP product gross margin of 76.4% in Q2 fiscal 2026, with a modest operating margin of 11% but strong gross margin fundamentals [6] - C3.ai's current stage of maturity, characterized by negative free cash flow and moderated gross margins, places it at a disadvantage compared to peers with proven operating models [7] Valuation and Estimates - C3.ai trades at a forward price-to-sales ratio of 7.86X, significantly lower than the industry average of 17.20X [11] - The Zacks Consensus Estimate for C3.ai's fiscal 2026 earnings per share (EPS) indicates a year-over-year decline of 224.4%, while fiscal 2027 EPS is expected to rise by 23.7% [12]

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance, leading to a significant drop in stock price following disappointing financial results [1][2]. Summary by Relevant Sections Allegations - The complaint claims that C3.ai's management provided overly positive statements while concealing material adverse facts about the company's growth, particularly the CEO's health affecting deal closures and overall performance [1]. - The company announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [1]. Stock Price Impact - Following the announcement on August 8, 2025, C3.ai's stock price fell from $22.13 per share to $16.47 per share by August 11, 2025, marking a decline of approximately 25.58% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from February 26, 2025, to August 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates throughout the case lifecycle [2].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. on behalf of investors who purchased shares during a specified period, indicating potential legal challenges for the company [1]. Summary by Relevant Sections - **Company Overview** - C3.ai, Inc. is facing a class action lawsuit initiated by Berger Montague PC, a national plaintiffs' law firm [1]. - **Class Period** - The lawsuit pertains to investors who acquired C3.ai securities from February 26, 2025, to August 8, 2025 [1]. - **Investor Deadline** - Investors interested in being appointed as lead plaintiff representatives must act by October 21, 2025 [1].

Core Viewpoint - C3.ai, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 26, 2025, and August 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management provided misleading positive statements while concealing adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in C3.ai during the relevant period have until October 21, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against C3.ai, titled Liggett v. C3.ai [1]

Group 1 - A class action securities lawsuit has been filed against C3.ai, Inc. [1] - The lawsuit is being notified by Levi & Korsinsky, LLP to investors in C3.ai [1] - C3.ai is listed on the New York Stock Exchange under the ticker symbol AI [1]

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance [3][4]. Company Summary - The class period for the lawsuit is from February 26, 2025, to August 8, 2025 [3]. - Allegations include that C3 AI's management provided overly positive statements while concealing material adverse facts about the company's growth potential and the CEO's health issues [3]. - On August 8, 2025, C3 AI announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing this to "the reorganization with new leadership" and the CEO's health [3]. - Following this announcement, C3 AI's stock price dropped from $22.13 per share to $16.47 per share, a decline of approximately 25.58% in just one day [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by October 21, 2025 [4]. - Registration allows shareholders to receive updates on the case and does not involve any cost or obligation [4]. Legal Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Investors in C3.ai, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's growth and the health of its CEO [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 8, 2025, C3.ai's management failed to disclose critical information, including the over-reliance on the CEO's health and effectiveness [2]. - Allegations include that the optimistic reports on growth, earnings potential, and margins were not reflective of the actual situation, as the CEO had not sufficiently recovered to fulfill his role [2]. Participation Information - Investors who suffered losses related to C3.ai are encouraged to participate in the lawsuit before the lead plaintiff deadline of October 21, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Insights - C3.ai, Inc. (AI) reported a weak start to fiscal 2026 with first-quarter revenues of $70.3 million, a decline of 19% year over year, primarily due to softer demand for demonstration licenses and disruptions from organizational changes [1][8] Revenue Breakdown - Subscription revenues were $60.3 million, making up 86% of total sales, indicating the stickiness of long-term contracts [2] - Demonstration licenses saw a significant decline of $15.9 million sequentially, which pressured overall revenue [2][8] - Professional services contributed $10 million, mainly from prioritized engineering services, but this was not enough to offset the revenue decline [3] Customer and Partner Activity - The company signed 28 new initial production deployments (IPDs) in the quarter, totaling 374, with 266 still active [4] - Approximately 90% of deals were partner-led, highlighting the importance of alliances with major cloud providers like Microsoft Azure, AWS, and Google Cloud [4] - Notable enterprise-scale wins with companies such as Nucor, Qemetica, and HII demonstrate the platform's applicability across various sectors [4] Future Guidance - Management expects fiscal second-quarter revenues to range from $72 million to $80 million, indicating a modest sequential improvement [5] - Despite near-term pressures from execution missteps and reliance on pilot-phase deployments, strong partner momentum and a growing pipeline of IPDs could stabilize revenue as fiscal 2026 progresses [5] Stock Performance and Valuation - C3.ai shares have declined 27.6% over the past three months, while the industry average fell by 7.4% [6] - The stock is currently trading at a forward 12-month price-to-sales (P/S) multiple of 7.50, significantly below the industry average of 17.10, suggesting an attractive investment opportunity [9] Earnings Estimates - The Zacks Consensus Estimate for C3.ai's fiscal 2026 loss per share has widened from 37 cents to $1.33 over the past 60 days [10] - Projections indicate a 224.4% fall in fiscal 2026 earnings, contrasting with expected growth for industry peers like Leidos, Vertiv, and Draganfly [13]